Baba, T., Kharma, B., Mandai, M., Yoshioka, Y., Hamanishi, J., Matsumura, N., … Konishi, I. (2012). Utilization of genomic signatures to identify Fludarabine and Temsirolimus as candidate drugs with high efficacy to chemo-refractory endometrial cancers. In Gynecologic Oncology (Vol. 125, pp. S138–S138). Elsevier BV. https://doi.org/10.1016/j.ygyno.2011.12.338

Baba, T., B. Kharma, M. Mandai, Y. Yoshioka, J. Hamanishi, N. Matsumura, K. Yamaguchi, S. Murphy, and I. Konishi. “Utilization of genomic signatures to identify Fludarabine and Temsirolimus as candidate drugs with high efficacy to chemo-refractory endometrial cancers.” In Gynecologic Oncology, 125:S138–S138. Elsevier BV, 2012. https://doi.org/10.1016/j.ygyno.2011.12.338.

Baba T, Kharma B, Mandai M, Yoshioka Y, Hamanishi J, Matsumura N, et al. Utilization of genomic signatures to identify Fludarabine and Temsirolimus as candidate drugs with high efficacy to chemo-refractory endometrial cancers. In: Gynecologic Oncology. Elsevier BV; 2012. p. S138–S138.

Baba, T., et al. “Utilization of genomic signatures to identify Fludarabine and Temsirolimus as candidate drugs with high efficacy to chemo-refractory endometrial cancers.” Gynecologic Oncology, vol. 125, Elsevier BV, 2012, pp. S138–S138. Crossref, doi:10.1016/j.ygyno.2011.12.338.

Baba T, Kharma B, Mandai M, Yoshioka Y, Hamanishi J, Matsumura N, Yamaguchi K, Murphy S, Konishi I. Utilization of genomic signatures to identify Fludarabine and Temsirolimus as candidate drugs with high efficacy to chemo-refractory endometrial cancers. Gynecologic Oncology. Elsevier BV; 2012. p. S138–S138.